Endocrinology, Vol 136, 4749-4753, Copyright © 1995 by Endocrine Society

ARTICLES

Metabolism of 1 alpha-hydroxyvitamin D2 to activated dihydroxyvitamin D 2 metabolites decreases endogenous 1 alpha, 25-dihydroxyvitamin D 3 in rats and monkeys

JC Knutson, BW Hollis, LW LeVan, C Valliere, KG Gould and CW Bishop
Bone Care International, Inc., Madison, Wisconsin 53713, USA.

The vitamin D analog 1 alpha-hydroxyvitamin D2 (1 alpha-OHD2) is under development for the treatment of secondary hyperparathyroidism and metabolic bone disease. This analog is metabolized in vivo to the natural active dihydroxylated metabolite of vitamin D2, 1 alpha,25- dihydroxyvitamin D2 [1 alpha,25-(OH)2D2]. To study the metabolism of this analog, an assay involving HPLC separation and purification of metabolites followed by RRA with the vitamin D receptor was developed to quantitate the active metabolites of the analog and the endogenous active metabolite of vitamin D3, 1 alpha,25-(OH)2D3, from the same blood sample. This assay was used to determine blood levels of active dihydroxylated vitamin D compounds in rats and monkeys treated with oral 1 alpha-OHD2. As the circulating 1 alpha,25-(OH)2D2 level increased dose dependently in these rats and monkeys, a concomitant decrease in the endogenous 1 alpha,25-(OH)2D3 was observed. In rats orally administered more than 2.5 micrograms 1 alpha-OHD2/kg.day, a second active metabolite of 1 alpha-OHD2, 1 alpha,24-(OH)2D2, was detected in concentrations similar to those of 1 alpha,25-(OH)2D2. These results indicate that the regulatory control of endogenous vitamin D metabolism as well as analog metabolism must be considered when assessing the therapeutic potential of a vitamin D analog.

This article has been cited by other articles:

				S. Attia, J. Eickhoff, G. Wilding, D. McNeel, J. Blank, H. Ahuja, A. Jumonville, M. Eastman, D. Shevrin, M. Glode, et al. Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer Clin. Cancer Res., April 15, 2008; 14(8): 2437 - 2443. [Abstract] [Full Text] [PDF]

				D. M. Albert, A. Kumar, S. A. Strugnell, S. R. Darjatmoko, J. M. Lokken, M. J. Lindstrom, and S. Patel Effectiveness of Vitamin D Analogues in Treating Large Tumors and During Prolonged Use in Murine Retinoblastoma Models Arch Ophthalmol, September 1, 2004; 122(9): 1357 - 1362. [Abstract] [Full Text] [PDF]

				D. M. Albert, A. Kumar, S. A. Strugnell, S. R. Darjatmoko, J. M. Lokken, M. J. Lindstrom, C. M. Damico, and S. Patel Effectiveness of 1{alpha}-Hydroxyvitamin D2 in Inhibiting Tumor Growth in a Murine Transgenic Pigmented Ocular Tumor Model Arch Ophthalmol, September 1, 2004; 122(9): 1365 - 1369. [Abstract] [Full Text] [PDF]

				R. J. Grostern, P. J. Bryar, M. L. Zimbric, S. R. Darjatmoko, B. J. Lissauer, M. J. Lindstrom, J. M. Lokken, S. A. Strugnell, and D. M. Albert Toxicity and Dose-Response Studies of 1{alpha}-Hydroxyvitamin D2 in a Retinoblastoma Xenograft Model Arch Ophthalmol, May 1, 2002; 120(5): 607 - 612. [Abstract] [Full Text] [PDF]

				S. L.-S. Fan, N. J. Schroeder, M. J. Calverley, J. M. Burrin, H. L.J. Makin, and J. Cunningham Potent suppression of the parathyroid glands by hydroxylated metabolites of dihydrotachysterol2 Nephrol. Dial. Transplant., December 1, 2000; 15(12): 1943 - 1949. [Abstract] [Full Text] [PDF]

				N. J. Schroeder and J. Cunningham What's new in vitamin D for the nephrologist? Nephrol. Dial. Transplant., April 1, 2000; 15(4): 460 - 466. [Full Text] [PDF]

				R. Brommage, C. E. Hotchkiss, C. J. Lees, M. W. Stancill, J. M. Hock, and C. P. Jerome Daily Treatment with Human Recombinant Parathyroid Hormone-(1-34), LY333334, for 1 Year Increases Bone Mass in Ovariectomized Monkeys J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3757 - 3763. [Abstract] [Full Text] [PDF]